Form 4: Pfizer CEO Albert Bourla Acquires Additional Phantom Stock Units Through Deferred Compensation Plan

Pfizer's Chairman and CEO, Albert Bourla, has reported the acquisition of 26 phantom stock units as part of the company's Nonfunded Deferred Compensation and Supplemental Savings Plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc. (PFE), acquired 26 phantom stock units on May 30, 2025.
• Each phantom stock unit represents one phantom share of common stock.
• The units were acquired at a price of $23.49 per unit.
• These units are part of the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Following this transaction, Mr. Bourla beneficially owns a total of 718,866 phantom stock units directly.
• The units are settled in cash upon the reporting person's separation from service and can be transferred into an alternative investment account at any time.

Sentiment

Score: 7

Explanation: The filing reports a routine acquisition of phantom stock units by the CEO as part of a deferred compensation plan, which is a standard executive compensation event and does not indicate any negative sentiment. It's a neutral to slightly positive signal as it shows continued participation in company plans.

Positives

• The acquisition of phantom stock units by the CEO indicates continued participation in the company's long-term incentive and deferred compensation plans.
• The transaction is part of a structured compensation plan, suggesting stability in executive remuneration practices.

Future Outlook

N/A

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction related to executive compensation within the pharmaceutical industry. It reflects standard practices for deferred compensation plans for senior executives in large publicly traded companies.

Related Party Transactions

• The acquisition of phantom stock units by Albert Bourla is a transaction with Pfizer Inc. as part of the company's Nonfunded Deferred Compensation and Supplemental Savings Plan, which constitutes a related party transaction as it involves an executive and the company.

Stakeholder Impact

• Shareholders: Minimal direct impact, as this is a routine compensation-related transaction and not a significant open market purchase or sale that would signal a change in management's outlook.
• Employees: No direct impact.

Key Dates

Recommendation

Keywords

Pfizer, PFE, Albert Bourla, SEC Form 4, Insider Transaction, Phantom Stock Units, Deferred Compensation, Executive Compensation, Biopharmaceutical, Pharmaceutical